Our bodies naturally make antibodies to fight infection. Monoclonal antibodies are lab-produced antibodies that are manufactured to mimic natural antibodies. Monoclonal antibodies for COVID-19 may block the virus that causes COVID-19 from attaching to human cells, making it more difficult for the virus to cause further harm. This is
given to people directly through an intravenous (IV) infusion.
We are currently only treating patients who test positive for COVID-19.
No. Vaccination remains the most powerful tool against contracting Covid-19, as well as against hospitalization and death from Covid, mAbs is a therapy that helps those who have tested positive to Covid-19 .
Yes. Those high risk patients who test positive for COVID-19 despite vaccination status are eligible to qualify to receive monoclonal antibody treatment.
Yes, though it is recommended you wait 90 days post-treatment to get vaccinated.
mAbs have been authorized by the FDA for emergency use. Any medical infusion or injection may cause side effects, such as brief pain, bleeding, bruising, soreness, swelling, fever, chills, exhaustion, nausea, headache, and possible infection at the infusion site. In rare cases, hypersensitivity and allergic reactions may also occur during or after an antibody infusion. For this reason, trained healthcare staff will monitor you during and after treatment. We highly recommend that you review the EUA Documentation for a full list of potential side effects of the medication.
No. Antibodies do not contain any live virus.
No, monoclonal antibodies are the synthetic antibodies given to early-stage COVID positive patients as an outpatient treatment. Convalescent plasma therapy uses the plasma (liquid portion of the blood) containing antibodies from recovered COVID-19 patients. Convalescent plasma therapy is currently used as inpatient treatment for hospitalized COVID-19 patients only at a more serious stage of their illness.
The monoclonal antibodies are delivered into a patient’s vein via intravenous (IV) infusion. If administered in one of our clinics or in your home the average time of a treatment is approximately 25 minutes for the infusion plus an hour for observation.
If treatment is administered in an ER, it can take between 1 to 6 hours depending on the wait time.
mAb treatments authorized by the U.S. Food and Drug Administration (FDA) for emergency use may help people who are at high risk for serious symptoms of the disease to:
a) Reduce the likelihood of needing to be admitted to the hospital or death.
b) Recover faster from COVID-19.
One possible side effect of monoclonal antibody therapy is an allergic reaction. These reactions typically only occur during infusion or soon after, and your care team will closely monitor for any signs of an allergic reaction. However, because an infusion reaction can also be delayed, contact your doctor immediately if you notice any of the following signs of an allergic reaction:
Fever and/or chills
Shortness of breath
Low blood pressure
Swelling of lips, face or throat
Hives or itchiness
mAb treatment must be given within 10 days of a person’s first symptoms of COVID-19. The sooner a person receives mAb treatment, the better.
If you think you may qualify for mAb treatments, speak with your doctor to see if you qualify, if you don't have a doctor contact us and we will connect you with a Doctor today. 1-866-TREAT-19.
While mAbs is considered one of the best treatments available for COVID-19, it is not the only treatment, speak with your doctor about treatments that are right for you.
The treatment should not be used for patients who:
The antibody treatment may make these conditions worse.